StockData
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. (CRDF) stock

CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$0.84−0.01 (-0.87%)

Close on Nov 18, 2026Market cap $65.27MP/E –Yield –

Cardiff Oncology operating margin

Operating margin is operating income as a percentage of revenue.

Cardiff Oncology's operating margin for the twelve months ending Jun 30, 2026 was -8320.1%. For fiscal 2025 it was -8256.3%, against -7123.1% the year before. The highest annual figure on record is -1076.6% in fiscal 2012.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-8256.3%−1133.2
FY2024Dec 31, 2024-7123.1%+2182.6
FY2023Dec 31, 2023-9305.7%+1031.6
FY2022Dec 31, 2022-10337.3%−2299.7
FY2021Dec 31, 2021-8037.6%−2822.9
FY2020Dec 31, 2020-5214.8%+1603.0
FY2019Dec 31, 2019-6817.8%−2310.2
FY2018Dec 31, 2018-4507.6%+556.8
FY2017Dec 31, 2017-5064.4%+5470.5
FY2016Dec 31, 2016-10534.9%−2455.4
FY2015Dec 31, 2015-8079.5%−2745.3
FY2014Dec 31, 2014-5334.2%−1210.5
FY2013Dec 31, 2013-4123.7%−3047.1
FY2012Dec 31, 2012-1076.6%+78.5
FY2011Dec 31, 2011-1155.2%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-9245.2%+2967.2
Q1 FY2026Mar 31, 2026-31341.5%−18147.0
Q4 FY2025Dec 31, 2025-3221.0%+5104.8
Q3 FY2025Sep 30, 2025-9978.3%−2341.4
Q2 FY2025Jun 30, 2025-12212.4%−4516.1
Q1 FY2025Mar 31, 2025-13194.5%−7861.3
Q4 FY2024Dec 31, 2024-8325.8%−1702.8
Q3 FY2024Sep 30, 2024-7637.0%+36.8
Q2 FY2024Jun 30, 2024-7696.3%+3607.4
Q1 FY2024Mar 31, 2024-5333.2%+9187.3
Q4 FY2023Dec 31, 2023-6623.1%+714.4
Q3 FY2023Sep 30, 2023-7673.8%+1996.1
Q2 FY2023Jun 30, 2023-11303.7%+172.1
Q1 FY2023Mar 31, 2023-14520.5%+444.4
Q4 FY2022Dec 31, 2022-7337.5%−175.1
Q3 FY2022Sep 30, 2022-9669.9%−1532.7
Q2 FY2022Jun 30, 2022-11475.8%−1344.9
Q1 FY2022Mar 31, 2022-14964.9%−7406.5
Q4 FY2021Dec 31, 2021-7162.4%−1702.7
Q3 FY2021Sep 30, 2021-8137.2%−4929.1
Q2 FY2021Jun 30, 2021-10130.9%−591.3
Q1 FY2021Mar 31, 2021-7558.3%−1493.6
Q4 FY2020Dec 31, 2020-5459.7%−826.4
Q3 FY2020Sep 30, 2020-3208.1%+4932.2
Q2 FY2020Jun 30, 2020-9539.5%+1464.8
Q1 FY2020Mar 31, 2020-6064.7%+323.1
Q4 FY2019Dec 31, 2019-4633.2%+626.6
Q3 FY2019Sep 30, 2019-8140.3%−3777.2
Q2 FY2019Jun 30, 2019-11004.4%−7033.8
Q1 FY2019Mar 31, 2019-6387.8%−1739.1
Q4 FY2018Dec 31, 2018-5259.9%−3214.3
Q3 FY2018Sep 30, 2018-4363.1%+337.8
Q2 FY2018Jun 30, 2018-3970.6%+1801.6
Q1 FY2018Mar 31, 2018-4648.7%+6005.6
Q4 FY2017Dec 31, 2017-2045.6%+12340.1
Q3 FY2017Sep 30, 2017-4700.9%+6450.2
Q2 FY2017Jun 30, 2017-5772.2%–
Q1 FY2017Mar 31, 2017-10654.3%–
Q4 FY2016Dec 31, 2016-14385.6%–
Q3 FY2016Sep 30, 2016-11151.1%–

More Cardiff Oncology figures

See a number that looks wrong?